Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Expects Q4 Revenue Jump of up to 26 Percent

NEW YORK (GenomeWeb News) - Bruker BioSciences today said it expects to report fourth-quarter revenue of between $130 million and $135 million — an increase of up to 26 percent over fourth-quarter 2005 revenues.
 
In a preliminary earnings statement issued today, Bruker said it expects full-year 2006 revenues in the range of $430 million to $435 million — growth of up to 17 percent over full-year 2005 revenues.
 
Bruker said that it has adjusted its historical financial results to account for its acquisition of Bruker Optics last July. As a result, the company reported pooled revenue of $106.8 million for the fourth quarter of 2005 and $372.3 million for the full year.
 
Bruker said it expects to report earnings of $.07 to $.09 per share for the fourth quarter.
 
Bruker said it expects "modest" improvement in income and revenue for the first quarter of 2007.
 
Bruker's CFO William Knight said the fourth quarter traditionally "has been our best quarter of the year, and our fourth quarter 2006 was particularly strong.
 
Bruker will release its full results for the fourth quarter and for the full year of 2006 on Feb. 22.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more